公开(公告)号：US20250057819A1

公开(公告)日：2025-02-20

申请号：US18719122

申请日：2022-12-22

Applicant: INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE

Inventor： Steven LAPLANTE ,  Richard Boulon ,  Clément Mazeaud ,  Alain Lamarre ,  Laurent Chatel-Chaix

IPC: A61K31/435 ,  A61K31/055 ,  A61K31/135 ,  A61K31/138 ,  A61K31/426 ,  A61K31/496 ,  A61K31/498 ,  A61K31/5377 ,  A61K31/5415 ,  A61K31/58 ,  A61K31/593 ,  A61K31/675 ,  A61K31/7068 ,  A61P31/14

Abstract: A combination comprising tilorone/nelfinavir; tilorone/molnupinavir; tilorone/remdesivir; tilorone/alfacalcidol: tilorone/clofazimine; tilorone/danazol; tilorone/manidipine; tilorone/sertraline; tilorone/trifluoperazine; remdesivir/hexachlorophene; remdesivir/mycophenolate; mycophenolate/hexachlorophene; mycophenolate/nelfinavir; or mycophenolate/nitazoxanide. This combination can be used for blocking the replication of a coronavirus in a coronavirus-infected cell, for treating an infection by a coronavirus in a subject, for treating a coronavirus-related disease in a subject, and/or for reducing the risk of developing a coronavirus-related disease or the severity of a coronavirus-related disease in a subject.

公开(公告)号：US20250012784A1

公开(公告)日：2025-01-09

申请号：US18707599

申请日：2022-11-11

Applicant: Academia Sinica

Inventor： Chi-Huey WONG ,  Ching-Chuan JIANG ,  Shang-Cheng HUNG ,  Chang-Hsun HSIEH ,  Pi-Hui LIANG ,  Ting-Jen CHENG ,  Hwai-I YANG

IPC: G01N33/53 ,  A61K31/135 ,  A61K31/167 ,  A61K31/192 ,  A61K31/196 ,  A61K31/405 ,  A61K31/485 ,  A61K31/5415 ,  A61K31/573 ,  A61K31/616 ,  A61K31/635

Abstract: Disclosed herein is a method for identifying and treating a subject having stages III or IV osteoarthritis (OA). The method includes steps of, determining the respective levels of chondroitin-4-sulfate (C4S) and chondroitin-6-sulfate (C6S) derived from a chondroitin sulfate (CS) chain of bikunin in a biological sample of the subject; calculating a risk score (RS) of the subject with the equation: R ⁢ S = 1 1 + e - f ⁡ ( x ) , in which f(x)=−9.3875+0.1356×(the age of the subject)+1.1493×(the level of C4S/the level of C6S) when the subject is a female, or f(x)=−10.3389+0.1356×(the age of the subject)+1.1493×(the level of C4S/the level of C6S) when the subject is a male; and treating the subject with an analgesic, a non-steroidal anti-inflammatory drug (NSAID), a corticosteroid or a combination thereof when the determined risk score is above 0.745.

公开(公告)号：US20250002486A1

公开(公告)日：2025-01-02

申请号：US18692503

申请日：2022-09-15

Applicant: Boundless Bio, Inc.

Inventor： Anthony B. PINKERTON ,  Jacques MAUGER ,  Yen Pham Hong TRUONG ,  Rachelle Janette ELSDON ,  Stephen Todd MEYER

IPC: C07D417/06 ,  A61K31/428 ,  A61K31/5415 ,  A61K31/542 ,  A61K31/554 ,  A61K45/06 ,  C07D513/04

Abstract: Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a cyclic sulfonamide RNR inhibitor disclosed herein.

公开(公告)号：US12171755B2

公开(公告)日：2024-12-24

申请号：US16758804

申请日：2018-10-25

Applicant: Children's Medical Center Corporation ,  The Brigham & Women's Hospital, Inc.

Inventor： Suneet Agarwal ,  Neha Nagpal ,  Yick Fong

IPC: A61K31/4706 ,  A61K31/341 ,  A61K31/353 ,  A61K31/381 ,  A61K31/4025 ,  A61K31/404 ,  A61K31/4162 ,  A61K31/4178 ,  A61K31/4188 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/428 ,  A61K31/429 ,  A61K31/433 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/472 ,  A61K31/473 ,  A61K31/4741 ,  A61K31/496 ,  A61K31/498 ,  A61K31/4985 ,  A61K31/499 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/52 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/538 ,  A61K31/5415 ,  A61K31/549 ,  A61K31/55 ,  A61K31/551 ,  C12Q1/66

Abstract: The disclosure relates to compounds that are, e.g., PAP Associated Domain Containing 5 (PAPD5) inhibitors and methods of use thereof.

公开(公告)号：US12171731B2

公开(公告)日：2024-12-24

申请号：US18200557

申请日：2023-05-22

Applicant: Duke University ,  National University of Singapore

Inventor： Dwight D. Koeberl ,  Paul M. Yen ,  Benjamin L. Farah

IPC: A61K31/155 ,  A61K31/05 ,  A61K31/12 ,  A61K31/137 ,  A61K31/167 ,  A61K31/192 ,  A61K31/198 ,  A61K31/216 ,  A61K31/277 ,  A61K31/352 ,  A61K31/355 ,  A61K31/385 ,  A61K31/436 ,  A61K31/519 ,  A61K31/522 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/575 ,  A61K31/7016 ,  A61K33/00 ,  A61K38/46 ,  A61K38/47 ,  A61P3/00

Abstract: The present disclosure is directed to methods of treating a steatosis- associated disorder by administering a therapeutic agent selected from a lysosomal enzyme, an autophagy-inducing agent, or a combination thereof. Steatosis-associated disorders discussed herein include GSD Ia, GSD Ib, GSD Ic, NAFLD, and NASH. Other embodiments are directed to methods of reversing steatosis, modulating autophagy, inducing autophagy, and reversing glycogen storage.

公开(公告)号：US20240415788A1

公开(公告)日：2024-12-19

申请号：US18781933

申请日：2024-07-23

Applicant: PhotoPharmics, Inc.

Inventor： Gregory Lynn Willis

IPC: A61K31/13 ,  A61K9/00 ,  A61K31/165 ,  A61K31/4515 ,  A61K31/454 ,  A61K31/5415

Abstract: A method for the treatment and/or prophylaxis of a neurological and/or neuropsychiatric disorder associated with altered dopamine function comprising administering to the eye of a patient in need thereof an effective amount of an agent that modulates neurotransmitter production or function.

公开(公告)号：US20240358711A1

公开(公告)日：2024-10-31

申请号：US18292918

申请日：2022-07-28

Applicant: IMMUNYX PHARMA LTD. ,  YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. ,  Hadasit Medical Research Services and Development Ltd.

Inventor： Seth Jonah SALPETER ,  Meital NAIM ,  Zvika GRANOT ,  Zvi Gregorio FRIDLENDER

IPC: A61K31/55 ,  A61K31/137 ,  A61K31/4706 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5415 ,  A61K45/06 ,  A61K47/64 ,  A61P29/00

CPC classification number: A61K31/55 ,  A61K31/137 ,  A61K31/4706 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5415 ,  A61K45/06 ,  A61K47/64 ,  A61P29/00

Abstract: Methods of inhibiting reactive oxygen species production by neutrophils or treating neutrophil-mediated inflammation in a subject by contacting the neutrophils with or administering an agent selected from a cyclin dependent kinase 4 (CDK4) inhibitor, a cyclin dependent kinase 6 (CDK6) inhibitor, an epidermal growth factor receptor (EGFR) inhibitor, a proto-oncogene tyrosine-protein kinase Src (SRC) inhibitor and a sodium (Na) channel blocker are provided. Pharmaceutical compositions comprising a nanoparticle, the agent and a neutrophil targeting peptide are also provided.

公开(公告)号：US20240336617A1

公开(公告)日：2024-10-10

申请号：US18611505

申请日：2024-03-20

Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

Inventor： E. James Petersson ,  Venkatesh Yarra

IPC: C07D487/04 ,  A61K31/4162 ,  A61K31/5377 ,  A61K31/5415 ,  G01N21/64 ,  G01N33/58

CPC classification number: C07D487/04 ,  A61K31/4162 ,  A61K31/5377 ,  A61K31/5415 ,  G01N21/6428 ,  G01N33/582 ,  G01N2021/6439

Abstract: In one aspect, the present disclosure relates to compounds of Formula (I). In certain embodiments, the compounds of Formula (I) comprise fluorescent dyes. In another aspect, the present disclosure provides a method for diagnosing a protein aggregation disease in a subject. In certain embodiments, the protein aggregation disease is selected from the group consisting of Parkinson's disease (PD) and Alzheimer's disease (AD).

公开(公告)号：US20240277726A1

公开(公告)日：2024-08-22

申请号：US18251923

申请日：2021-11-03

Applicant: Mylan Laboratories LTD

Inventor： Pankaj Devidas Patil ,  Vivekanand Khyamgonde ,  Ritesh Kakaria ,  Ashish Jaiswal ,  Akhilesh Dixit ,  Santanu Chakraborty ,  Amit Antarkar ,  Abhijit Deshmukh ,  Jeffrey P. Smith

IPC: A61K31/5415 ,  A61K9/20 ,  A61K9/50

CPC classification number: A61K31/5415 ,  A61K9/2009 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2081 ,  A61K9/5078

Abstract: The present invention relates to novel pharmaceutical composition comprising meloxicam for the treatment of acute pain, wherein the composition comprises at least a hydrophilic polymer and one or more alkalizing agents or combinations thereof.

公开(公告)号：US20240261407A1

公开(公告)日：2024-08-08

申请号：US18636093

申请日：2024-04-15

Applicant: Axsome Therapeutics, Inc.

Inventor： Herriot Tabuteau

IPC: A61K47/02 ,  A61K9/00 ,  A61K9/20 ,  A61K31/4439 ,  A61K31/5415 ,  A61K45/06 ,  A61K47/40 ,  A61K47/69 ,  C08B37/16

CPC classification number: A61K47/02 ,  A61K9/0053 ,  A61K9/2009 ,  A61K31/4439 ,  A61K31/5415 ,  A61K45/06 ,  A61K47/40 ,  A61K47/6951 ,  C08B37/0012 ,  C08B37/0015

Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.